Ameriprise
RVMD icon

Ameriprise’s Revolution Medicines RVMD Stock Holding History

Ameriprise’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$154M Sell
1,579,793
-477,064
-23% -$48.2M 0.04% 430
2025
Q4 		$164M Buy
2,056,857
+832,098
+68% +$54.6M 0.04% 425
2025
Q3 		$57.2M Sell
1,224,759
-119,701
-9% -$4.69M 0.01% 814
2025
Q2 		$49.5M Sell
1,344,460
-146,198
-10% -$5.62M 0.01% 869
2025
Q1 		$52.7M Sell
1,490,658
-136,190
-8% -$5.53M 0.01% 817
2024
Q4 		$71.2M Buy
1,626,848
+141,426
+10% +$7.14M 0.02% 681
2024
Q3 		$67.4M Buy
1,485,422
+13,132
+0.9% +$572K 0.02% 713
2024
Q2 		$57.1M Sell
1,472,290
-222,211
-13% -$8.31M 0.02% 738
2024
Q1 		$54.6M Buy
1,694,501
+71,480
+4% +$2.12M 0.02% 770
2023
Q4 		$46.5M Buy
1,623,021
+411,165
+34% +$9.88M 0.01% 809
2023
Q3 		$33.5M Sell
1,211,856
-11,869
-1% -$352K 0.01% 933
2023
Q2 		$32.7M Buy
1,223,725
+99,767
+9% +$2.45M 0.01% 971
2023
Q1 		$24.3M Buy
1,123,958
+423,035
+60% +$10.4M 0.01% 1139
2022
Q4 		$16.7M Sell
700,923
-292,140
-29% -$6.21M 0.01% 1327
2022
Q3 		$19.6M Sell
993,063
-8,245
-0.8% -$181K 0.01% 1196
2022
Q2 		$19.5M Buy
1,001,308
+30,794
+3% +$599K 0.01% 1221
2022
Q1 		$24.8M Buy
970,514
+9,218
+1% +$201K 0.01% 1193
2021
Q4 		$24.2M Buy
961,296
+2,069
+0.2% +$58.3K 0.01% 1275
2021
Q3 		$26.4M Buy
959,227
+21,742
+2% +$633K 0.01% 1076
2021
Q2 		$29.7M Buy
937,485
+517,478
+123% +$18.1M 0.01% 1072
2021
Q1 		$19.3M Buy
420,007
+148,682
+55% +$6.67M 0.01% 1355
2020
Q4 		$10.7M Buy
271,325
+221,086
+440% +$8.74M ﹤0.01% 1704
2020
Q3 		$1.75M Buy
50,239
+5,795
+13% +$161K ﹤0.01% 2737
2020
Q2 		$1.4M Sell
44,444
-19,091
-30% -$600K ﹤0.01% 2768
2020
Q1 		$1.39M Buy
+63,535
New +$1.76M ﹤0.01% 2668

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise's RVMD Position: Q1 2026 in Review

Ameriprise reduced its Revolution Medicines (RVMD) stake by 23% in Q1 2026, selling an estimated $48.2M and leaving 1,579,793 shares worth $154M. The position accounts for 0.04% of the portfolio, ranked #430.

Ameriprise first reported a position in RVMD in Q1 2020 and has held it in 25 quarters since. The position peaked at $164M in Q4 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Ameriprise held 1,579,793 shares of Revolution Medicines worth $154M as of Q1 2026.
  • Ameriprise sold 477,064 Revolution Medicines shares in Q1 2026, an estimated $48.2M.
  • Revolution Medicines made up 0.04% of Ameriprise's portfolio in Q1 2026, its #430 holding.
  • Ameriprise first reported a position in Revolution Medicines in Q1 2020 and has held it in 25 quarters since.
  • Ameriprise's Revolution Medicines position peaked at $164M in Q4 2025.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.